At the Drug Development Summit in Boston, MA, a biotech startup Temprian Therapeutics announced a key in-license deal from Northwestern University.
The pending patent forms the backbone for TT-01, a DNA-based drug under development by Temprian Therapeutics. This drug candidate uses the modified heat shock protein -- HSP70i -- developed by Prof. Caroline Le Poole at Northwestern and Loyola Universities. Heat shock protein is a type of proteins, which are produced by cells during stressful situations, to cope with insulting factors and to mediate organism's responce. For example, previous studies have reported that overexpression of HSP70 can delay the progression of Parkinson disease and Alzheimer disease.
In theory, HSP70i mediates depigmentation process driven by the normal defensive immune mechanicsm known as "killer" T-cells. Rouge T-cells mistakenly identify healthy melanocytes as intruders and kill them. HSP70i may be regarded as a target candidate for stopping rouge T-cells and thereby reversing an autoimmune process. However, it is unknown whether selective inactivation of T-cells and dampening autoimmune responses will have consequences for other, healthy immune responses.
If successful, this drug would be an effective tool kit to stop vitiligo progression, to stimulate the repigmentation, and to prevent relapse. Four needleless DNA plasmid injections are supposed to cause a repigmentation across the entire body, even at distant lesions. "The treatment effect might be temporary, yet long-lasting," says Dr. Kettil Cedrcreutz, CEO Temprian Therapeutics.
Earlier this year the company completed a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) and raised $325,000 of seed financing, according to Dr. Cedercreutz. "We are planning to start clinical trials in 2021. Upon attaining FDA approval TT-01 would secure market exclusivity for twelve years as a new biologic."
For other companies currently developing drugs for vitiligo, read our exclusive Vitiligo Market Insights And Biotech Pipeline Analysis. This report will help you to understand competitive environment for vitiligo therapies, the key biotech companies involved in vitiligo drug development, along with its clinical trial status, pharmacological action, agreements and collaborations, and stock price trajectory. A report like this would cost $2,000 minimum elsewhere, but as a friend of VR Foundation, you can read this free.
- Will it spread?
Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...
- How long does it take to treat vitiligo?
Treatment results will vary by person and type of vitiligo. The rule of thumb is that you will need to allow at least 3 to 6 months before you begin to see results from any trea...
- Is vitiligo contagious?
Vitiligo is NOT contagious. It cannot be passed on or caught from touching someone with vitiligo, shaking hands, swimming in the same pool, sharing towels, sitting next to someo...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.